US Pharma MarketingCMS seeks to close Medicare negotiation
CMS has proposed a policy to close what it says is a loophole that could help drugmakers avoid Medicare negotiations by making small changes to their existing drugs. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act…
CMS has proposed a policy change that clarifies its stance on how products are grouped together for Medicare negotiations.
Under the Inflation Reduction Act, biologics become eligible for Medicare negotiations 11 years after their approval ...
Source: Endpoints News